A shot analysts projected as a multibillion-dollar seller produced results “well below” the company’s expectations, ...

Moderna is halting development of an mRNA vaccine for congenital cytomegalovirus after its candidate failed to protect women ...

Moderna stock toppled Thursday after the biotech company's experimental CMV vaccine failed in a Phase 3 study of 7,500 women.

(NASDAQ:MRNA) today announced topline results from a Phase 3 pivotal trial evaluating the efficacy of mRNA-1647, the ...

Moderna said its experimental vaccine for cytomegalovirus failed in a key trial, a significant setback for a company already ...

Moderna said its cytomegalovirus (CMV) vaccine, mRNA-1647, failed to prevent infection in women of childbearing age in a ...

A key question for investors going forward will be whether Moderna's other latent virus vaccines for Epstein-Barr and ...

While development has been scrapped in CMV, a Phase II trial investigating the candidate in bone marrow transplant patients ...

Moderna ends its CMV vaccine program after a Phase 3 trial failed to meet efficacy goals, but maintains its 2028 breakeven ...

Moderna announced its decision to cease development of its vaccine mRNA-1647, which was being designed to treat birth defects ...

Moderna announced in October 2025 that it will discontinue development of its investigational cytomegalovirus (CMV) vaccine, ...

The vaccine, known as mRNA-1647, showed disappointing efficacy against primary CMV infection in healthy women, ranging from just 6% to 23% depending on the case definition used. As a result, Moderna ...